Repository of Research and Investigative Information

Repository of Research and Investigative Information

Hormozgan University of Medical Sciences

Insights into the role of HCV Plus-/Minus strand RNA, IFN-gamma and IL-29 in relapse outcome in patients infected with HCV

(2015) Insights into the role of HCV Plus-/Minus strand RNA, IFN-gamma and IL-29 in relapse outcome in patients infected with HCV. Pacific Journal of Allergy and Immunology.

[img]
Preview
Text
Insights_into_the_role_of_HCV_.pdf

Download (1MB) | Preview

Official URL: http://apps.webofknowledge.com/full_record.do?prod...

Abstract

Background and Objectives: Approximately one-third of hepatitis C virus (HCV) infected patients who complete antiviral therapy with undetectable serum HCV RNA at the end of therapy (ETR), will experience relapse. The reasons for the failure of treatment have not been elucidated. It was showed that HCV RNA can persist and replicate in extra hepatic sites, e.g. in peripheral blood mononuclear cells (PBMCs), but the relevance of its presence with relapse over time is still unknown. Moreover, interferon-gamma (IFN-gamma) and IFN-lambdas [IFN-interleukin-29 (IL-29)], possess potent antiviral activity. We studied if the presence of plus-/minus strand RNA in PBMCs of patients and the serum level of IFN-gamma and IL-29, which is the most abundant IFN-lambdas in serum, can be considered as predictive factors in relapse outcomes. Methods: Patients were screened for plus-/minus strand RNA at ETR and after 6 months. Also, we measured the serum level of IFN-gamma and IL-29 and compared the result with those who developed a sustained virological response (SVR). Results: Levels of IL-29 and IFN-gamma serum were significantly higher in SVR at ETR and 6 months later compared to those of the relapsed patients, but there was no difference between the two groups regarding the presence or absence of plus-/minus HCV strand in PBMCs. Conclusions: Our novel findings showed that the serum level of IL-29 and IFN-gamma are predictive of relapse outcomes to HCV treatment, but there was no association between the presence of plus-/minus HCV RNA in PBMCs of patients with an outcome of therapy at ETR and later.

Item Type: Article
Keywords: IL-29; IFN-gamma; Relapsed; HCV CHRONIC HEPATITIS-C; BLOOD MONONUCLEAR-CELLS; SUSTAINED VIROLOGICAL RESPONSE; PEGYLATED-INTERFERON-ALPHA; RIBAVIRIN THERAPY; VIRUS-INFECTION; GENOTYPE 1; REPLICATION; LAMBDA; SERUM
Subjects: WC Communicable Diseases > WC 500-590 Virus Diseases
Depositing User: مهندس هدی فهیم پور
URI: http://eprints.hums.ac.ir/id/eprint/5335

Actions (login required)

View Item View Item